Full-Time

Manager Process Sciences-Downstream

Posted on 4/19/2025

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

Compensation Overview

$90.8k - $203k/yr

Senior, Expert

Albany, NY, USA

Category
Lab & Research
Interdisciplinary Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • BS/BA in life sciences, chemical engineering, chemistry or related field
  • Previous leadership experience is required
  • 6+ years of experience for Associate Manager Process Sciences
  • 7+ years of experience for Manager Process Sciences
  • 8+ years of experience for Sr. Manager Process Sciences
  • Proficient lab skills in protein separation, filtration and purification using GE AKTA system
  • Experience with scale-down model development
  • Solid understanding of word processing, spreadsheet, database management, graphing, and advanced presentation
  • Strong project management, interpersonal, cross-cultural, communication, negotiation and problem-solving skills
Responsibilities
  • Oversee a group in collaborative investigations
  • Participate in new technology initiative efforts and continuous improvement projects
  • Responsible for leading, mentoring, and developing direct reports
  • Performs technical investigations and creates associated reports
  • Develops, writes, and reviews technical documents, including protocols, reports, and memos
  • Supervise scaled-down downstream purifications for investigational support
  • Serve as a subject matter expert (SME) for manufacturing downstream operations (chromatography), data analysis and manufacturing support activities
  • Assists in the analysis of samples generated from lab scale studies
  • Maintains lab supplies and equipment
  • Produces and maintains accurate records meeting or exceeding data integrity requirements
  • Participates in process and quality risk assessments
  • Participates in tech transfer activities
  • Present experimental results to the management
Desired Qualifications
  • Enjoy design of experiments, Mechanistic Modeling, and advanced statistical analysis
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its development process. Unlike many competitors, Regeneron focuses on both research and commercialization, generating revenue through the sale of its approved medicines and strategic partnerships. The goal of Regeneron is to improve patient outcomes by providing effective treatments and ensuring they meet safety and efficacy standards.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Regeneron is expanding its Tarrytown campus, creating 1,000 high-skill jobs.
  • Dupixent approved as first targeted therapy for chronic spontaneous urticaria in a decade.
  • Regeneron invests in AI and machine learning for efficient drug discovery.

What critics are saying

  • Heavy investment in Tarrytown expansion poses financial risk if returns don't materialize.
  • Dependency on Fujifilm partnership may pose operational challenges.
  • FDA rejection of Dupixent for CSU highlights regulatory setback risks.

What makes Regeneron Pharmaceuticals unique

  • Regeneron leverages proprietary VelociSuite technologies for rapid biologic development.
  • The company collaborates with academic institutions to enhance R&D efforts.
  • Regeneron focuses on bispecific antibodies for comprehensive treatment approaches.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

Pharma Journalist
Apr 24th, 2025
Regeneron Invests in Expanding Biologic Medicine Manufacturing

Regeneron continues to invest heavily in its New York State operations, where an approximately $3.6 billion expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and expanding research, preclinical manufacturing and support facilities.

PharmiWeb
Apr 24th, 2025
Dupixent Approved In The Us As The First New Targeted Therapy In Over A Decade For Chronic Spontaneous Urticaria

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Kenneth MendezPresident and Chief Executive Officer at the Asthma and Allergy Foundation of America“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives. The approval of this treatment offers patients more options and the chance to control their disease.”Alyssa Johnsen, M.D., Ph.D.Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi“CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU patients who previously had limited treatment options.”The US approval is based on data from two phase 3 clinical studies, Study A (n=136) and Study C (n=148), which included biologic-naïve patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both studies met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity (a composite of itch and hives) compared to placebo at 24 weeks

Texas Border Business
Apr 23rd, 2025
America's Manufacturing Power Surges as Global Giants Invest Billions

Additionally, Regeneron is investing approximately $3.6 billion to expand its Tarrytown, New York facility, aiming to double its manufacturing capabilities nearly.

Pharmaceutical Technology
Apr 22nd, 2025
Regeneron partners with Fujifilm to broaden manufacturing capacity

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity.

BioSpace
Apr 14th, 2025
Fda Action Alert: Regeneron, Sanofi And Abeona

The FDA has three big decisions slated for the back half of April, two of which are for Regeneron’s blockbuster franchises.Read below for more.Regeneron, Sanofi Eye Another Expansion for DupixentFollowing an initial rejection in October 2023, Regeneron and Sanofi are again trying to expand their anti-inflammatory antibody Dupixent into chronic spontaneous urticaria (CSU). The FDA’s decision is due on April 18.To support their bid for label expansion, the pharma partners submitted data from the Phase III LIBERTY-CUPID clinical program. Data from Study A, released in July 2021, showed that Dupixent could nearly double itch reduction and urticaria activity scores versus antihistamines. Study B, meanwhile, found a numeric improvement in itching and hives versus antihistamines in patients refractory to omalizumab, as per a February 2022 readout, though the study did not reach statistical significance. It was terminated due to futility.These two studies formed the backbone of Dupixent’s initial failed attempt at an approval for CSU, which the FDA rebuffed due to the lack of efficacy data. In their resubmission, Regeneron and Sanofi filed additional data from a third trial, dubbed Study C, which also showed a nearly 50% drop in itch and urticaria activity.If approved, Dupixent would be the first targeted option for CSU in a decade, according to a November 2024 news release.Regeneron Proposes Longer Dosing Interval for Eylea HDIn a bid to maintain the market dominance of its blockbuster biologic Eylea, Regeneron is working to improve the product profile of the high-dose (HD) formulation of the drug

INACTIVE